Cost-effectiveness Analysis of Three Corticosteroids in ILDs

• Status: Completed
• Trial end date: 2020-03-15
• Target enrollment: 0
• Participant gender: All

Summary

This was a 3 months prospective, open label, and parallel study to test the efficacy of 3 different corticosteroids in the management of interstitial lung diseases. Followed by a pharmacoeconomic analysis to find which regimen (betamethasone, dexamethasone or prednisolone) is the most cost-effective.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Betamethasone; Dexamethasone; Prednisolone

Criteria

Inclusion Criteria:

• Patients with ILD (hypersensitivity pneumonitis) with age between18 and 65 years old.

• Symptoms including dry cough and shortness of breath.

• Significant decrease in pulmonary function (desaturation by 4% after 6-minute walk distance), where the patients were no more controlled on their prednisolone maintenance therapy (up to 10 mg/day).

• Chest CT showing ground glass opacity and band of shadow.

Exclusion Criteria:

• Patients with any other organ affliction (heart failure (ejection fraction 40-50%), renal failure (decrease in glomerular filtration rate > 75%), or liver cirrhosis (transient elastography liver stiffness measurements 12.5-75.5 kPa)).

• Active infection.

• Patients on other immunosuppressive medications (e.g., cyclophosphamide) and anti-fibrotic (e.g., interferon, pirfenidone, endothelin-1 antagonist and tumor necrosis factor α modulator).

• History of pulmonary embolism (corticosteroids' use increase the risk of recurrence of pulmonary embolism).

• Pregnancy.